-
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Rituximab is not effective for the treatment of fatigue in primary biliary cholangitis
- Thread starter jaybee00
- Start date
As I vaguely remember it there was a study that was allocated CFS funds into a study similar to this.
http://www.southampton.ac.uk/news/2013/04/patients-with-chronic-fatigue.page
Researchers at the launch will be discussing some of the key issues they are facing and the areas that are making progress. They will also be explaining some of their thoughts for future research and their latest preliminary findings. These include, why some patients experience significant pain that is unresponsive to pain killers; whether using a monoclonal antibody (Rituximab), which is highly successful in treating rheumatoid arthritis, some cancers and the profound fatigue experienced in patients with an immune liver disease known as primary biliary cirrhosis, could be used as a test experimental medicine approach in order to understand more about fatigue mechanisms; and the link between blood pressure problems and CFS patients.
http://www.southampton.ac.uk/news/2013/04/patients-with-chronic-fatigue.page
Researchers at the launch will be discussing some of the key issues they are facing and the areas that are making progress. They will also be explaining some of their thoughts for future research and their latest preliminary findings. These include, why some patients experience significant pain that is unresponsive to pain killers; whether using a monoclonal antibody (Rituximab), which is highly successful in treating rheumatoid arthritis, some cancers and the profound fatigue experienced in patients with an immune liver disease known as primary biliary cirrhosis, could be used as a test experimental medicine approach in order to understand more about fatigue mechanisms; and the link between blood pressure problems and CFS patients.